Myeloma

The FDA plans to speed up its review of HPN217 for the treatment of patients with relapsed, refractory multiple myeloma who have received at least four prior lines of therapy.

From Emilio Delgado, the actor who portrayed Luis on “Sesame Street”, dying from multiple myeloma to actor Benjamin Bratt discussing his wife’s breast cancer journey, here’s what’s happening in the cancer space this week.

The recent FDA approval of the CAR-T cell therapy Carvykti represents a life-changing advancement for patients with multiple myeloma whose disease progressed after countless other treatments, according to an expert.

Maintenance therapy with Ninlaro and Revlimid in patients with recently diagnosed multiple myeloma who underwent a stem cell transplant may safely improve survival, although more research is needed especially in high-risk patients.

Maintaining a healthy diet during treatment may help combat side effects.

Although multiple myeloma survival rates have improved over the past 20 years, the survival gap among socioeconomic groups has widened.

As part of its Speaking Out video series, CURE spoke with Throwing Bones founder, Kenny Caps, about improving patient-physician communication throughout myeloma care.

As part of its Speaking Out video series, CURE spoke with Throwing Bones founder, Kenny Caps, about treating myeloma as a chronic disease and how the multidisciplinary approach to care can assist in challenges, like financial toxicity.

As part of its Speaking Out video series, CURE spoke with Throwing Bones founder, Kenny Caps, about raising awareness for multiple myeloma, and why sharing one’s story is helpful for others.

Ninety-eight percent of patients with pretreated relapsed/refractory myeloma responded to treatment with Carvykti, a newly approved CAR-T cell therapy for this patient population.

A clinical trial to evaluate Descartes-25, a novel allogeneic RNA cell therapy, for multiple myeloma has officially treated its first patient and is now recruiting in certain locations.

Although patients with multiple myeloma may be concerned that a reduction in treatment dose may be less effective, an expert from The Tisch Cancer Institute stresses that it may be more beneficial.

The Food and Drug Administration is expected to decide on whether to approve certain cancer regimens within the first few months of the year. Here’s what patients with cancer should know.

An expert from the Mayo Clinic explained that the use of a combination of drugs including Darzalex in the first-line setting may lead to better outcomes for patients with multiple myeloma instead of other first-line standard-of-care options.

From an overview of the disease to notable deaths and clinicians who go the extra mile, here is a list of CURE®’s most-read myeloma articles from 2021.

Patients with cancer who received two full vaccine doses but developed breakthrough COVID-19 infections afterwards had a 13% mortality rate as well as a high hospitalization risk, and therefore should maintain protective strategies, according to experts.

New findings show that 43% of patients with certain blood cancers produced COVID-19 antibodies after receiving a third full dose of the mRNA vaccine.

A certified oncology nurse and board-certified adult nurse practitioner explained how the recent FDA approval of Darzalex Faspro, Kyprolis and dexamethasone may allow patients with relapsed/refractory multiple myeloma to switch treatments after discovering their current treatment is no longer working.

Treatment with the CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel) led to a 97.9% response rate at two years in patients with relapsed/refractory myeloma in a recent clinical trial.

Two different doses of Venclexta combined with Darzalex and the steroid dexamethasone elicited effective responses appeared safe in patients with t(11;14) relapsed/refractory multiple myeloma.

Treatment with Ninlaro plus Darzalex and a low dose of the steroid dexamethasone was associated with favorable responses to treatment in non-transplant eligible, intermediate-fit patients with newly diagnosed multiple myeloma.

Researchers found that depression and anxiety may skew patient perceptions of participating in blood cancer clinical trials, thus contributing to low enrollment throughout the United States.

In recent trial results, a dose reduction of Xpovio (selinexor) was associated with longer progression-free survival and duration of response while also reducing side effects in patients with multiple myeloma.

The FDA approved the three-drug regimen of Darzalex Faspro, Kyprolis and dexamethasone for patients with pretreated relapsed/refractory multiple myeloma.

Darzalex plus Revlimid and dexamethasone may be the preferred option to treat older patients with multiple myeloma who are ineligible for stem-cell transplant.

An expert explains how two common myeloma treatments – CAR-T cell therapy and bi-specific antibodies – work, and which patients may want to steer clear from these treatment modalities.

Myeloma survivors, their loved ones and clinicians trekked up the Alaska-Kenai Peninsula to raise money and funds for the disease, offering one nurse the inspiration she needed after more than a year of the COVID-19 pandemic.

Engineered cell technology is an example of ingenuity that brings together cutting-edge laboratory science and clinical trials to address aggressive cancers.

Colin Powell has died of complications from COVID-19 after receiving treatment for a blood cancer.

After receiving a diagnosis of multiple myeloma, a patient relied on the Multiple Myeloma Research Foundation for information and is becoming part of the conversation.